Population, n = 84 | NoRifampicin | Rifampicin | p |
---|---|---|---|
n = 39, (%) | n = 45, (%) | ||
Age, mean ± SD | 68.59 ± 11.23 | 62.02 ± 10.93 | 0.006 |
Diabetes mellitus | 10 (40.0%) | 15 (60.0%) | 0.441 |
Body mass index, mean ± SD | 25.31 ± 4.28 | 25.72 ± 4.61 | 0.676 |
Creatinine clearance <60 ml/min | 70.33 ± 31.95 | 86.07 ± 34.68 | 0.035 |
Immunodepression | 5 (33.3%) | 10 (66.7%) | 0.261 |
Chronic obstructive pulmonary disease | 11 (50.0%) | 11 (50.0%) | 0.15 |
Coronary disease | 24 (50.0%) | 24 (50.0%) | 0.448 |
Aortic aneurysm | 16 (50.0%) | 16 (50.0%) | 0.606 |
Presumed PVGI | 1 (12.5%) | 7 (87.5%) | 0.043 |
Definite PVGI | 38 (50.0%) | 38 (50.0%) | 0.043 |
Early definite PVGI (<4 months) | 24 (57.1%) | 18 (42.9%) | 0.049 |
Late definite PVGI (> 4 months) | 14 (41.2%) | 20 (58.8%) | 0.426 |
Extracavitary PVGI | 19 (50.0%) | 19 (50.0%) | 0.550 |
Fever > 38°C | 26 (46.4%) | 30 (53.6%) | 0.865 |
Fissuration/disruption | 2 (22.2%) | 7 (77.8%) | 0.125 |
False aneurysm | 7 (63.6) | 4 (36.4) | 0.209 |
White blood cells count (G/l) | 11410.7 ± 4463.2 | 10882.1 ± 4162.3 | 0.0645 |
Mean ± SD | |||
Autologous vein | 9 (75.0%) | 3 (25.0%) | 0.032 |
Arterial homo/allograft | 9 (37.5%) | 15 (62.5%) | 0.299 |
New prosthesis | 4 (50.0%) | 4 (50.0%) | 0.831 |
Debridement | 2 (50.0%) | 2 (50.0%) | 0.883 |
Medical treatment (no surgery) | 5 (38.5%) | 8 (61.5%) | 0.531 |
Adequate empirical antibiotherapy | 37 (46.8%) | 42 (53.2%) | 0.766 |
New surgery | 9 (36.0%) | 16 (64.0%) | 0.165 |
Admission to intensive care unit | 22 (62.9%) | 13 (37.1%) | 0.010 |
Septic shock at initial presentation | 8 (53.3%) | 7 (46.7%) | 0.554 |
Post-operative dialysis | 3 (75.0%) | 1 (25.0%) | 0.240 |
Death related to PVGI | 11 (78.6%) | 3 (21.4%) | 0.008 |